Pembrolizumab Monotherapy or Combination Therapy for Bone Metastases in Advanced Non-Small Cell Lung Cancer

ECOG PS, Eastern Cooperation Oncology Group performance status; EGFR, epidermal growth factor receptor; NSCLC, non-small cell lung cancer; PD-L1, programmed cell death-ligand 1.

*, P<0.05. PFS, progression-free survival; OS, overall survival; ECOG PS, Eastern Cooperation Oncology Group performance status; HR, hazard ratio.

Authors and Disclosures

Huiping Qiang^1#, Yuqiong Lei^2#, Yinchen Shen¹, Jiaqi Li¹, Hua Zhong¹, Runbo Zhong¹, Xueyan Zhang¹, Qing Chang¹, Jiahuan Lu¹, Hui Feng¹, Yan Zhu¹, Alfredo Addeo³, Giuseppe L. Banna⁴, In-Jae Oh⁵, Jialin Qian^1# and Tianqing Chu<sup>1#

1</sup>Department of Respiratory Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China; ²Department of Respiratory Medicine, Shanghai Sixth People's Hospital, Shanghai Jiao Tong University, Shanghai, China; ³Oncology Department, University Hospital of Geneva, Geneva, Switzerland; ⁴Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Turin, Italy; ⁵Department of Internal Medicine, Chonnam National University Medical School and Hwasun Hospital, Jeonnam, Republic of Korea

Correspondence to
Jialin Qian; Tianqing Chu. Department of Respiratory Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University, No. 241, Huaihai West Road, Shanghai 200030, China. Email: jialin_qian@aliyun.com; tianqing_chu@126.com.

Contributions
(I) Conception and design: J Qian, T Chu; (II) Administrative support: None; (III) Provision of study materials or patients: Y Shen, H Zhong, R Zhong, X Zhang, J Qian, T Chu; (IV) Collection and assembly of data: J Li, Q Chang, J Lu, H Feng, Y Zhu; (V) Data analysis and interpretation: H Qiang, Y Lei; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

^#These authors contributed equally to this work.

Conflicts of Interest
All authors have completed the ICMJE uniform disclosure form (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-21-1033/coif). Dr. AA reports that he received personal fees for attending advisory from Bristol-MyersSquibb, AstraZeneca, Roche, Pfizer, Merck Sharp and Dohme, Astella, Eli Lilly and Boehringer-Ingelheim and received fees for speaking bureau for Eli Lilly, AstraZeneca, MSD for work performed outside of the current study. Dr. GLB has received consulting fees from AstraZeneca, and payment or honoraria for lectures, presentations, speakers' bureaus, manuscript writing or educational events from AstraZeneca and Astellas. Dr. IJO has received research funding from Roche, and consulting fees from Roche, Ono, MSD, Pfizer, Boehringer-Ingelheim, AstraZeneca and Takeda. The other authors have no conflicts of interest to declare.